With over 85 years of experience in the industry, Catalent supports our partners in introducing 200 new products and manufacturing over 70 billion doses each year. We became a publicly-traded company (NYSE: CTLT) in 2014 and have grown to become a vibrant community of more than 13,000 employees supporting over 7,000 products for over 1,000 customers all around the world. At Catalent, we share a common goal, to put patients first and help people around the world live better and healthier lives. Catalent’s Bloomington location provides drug substance manufacturing, drug product manufacturing, and related pharmaceutical services. This award-winning facility helps customers accelerate biologic drug development programs.